Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) EBIT Margin (2020 - 2025)

Tango Therapeutics has reported EBIT Margin over the past 6 years, most recently at 26.15% for Q3 2025.

  • Quarterly results put EBIT Margin at 26.15% for Q3 2025, up 30941.0% from a year ago — trailing twelve months through Dec 2025 was 34.2% (up 31188.0% YoY), and the annual figure for FY2025 was 34.2%, up 31189.0%.
  • EBIT Margin for Q3 2025 was 26.15% at Tango Therapeutics, up from 1287.87% in the prior quarter.
  • Over the last five years, EBIT Margin for TNGX hit a ceiling of 26.15% in Q3 2025 and a floor of 1287.87% in Q2 2025.
  • Median EBIT Margin over the past 5 years was 432.41% (2022), compared with a mean of 440.58%.
  • Peak annual rise in EBIT Margin hit 30941bps in 2025, while the deepest fall reached -113918bps in 2025.
  • Tango Therapeutics' EBIT Margin stood at 384.6% in 2021, then dropped by -24bps to 476.79% in 2022, then tumbled by -35bps to 644.69% in 2023, then plummeted by -54bps to 993.68% in 2024, then skyrocketed by 103bps to 26.15% in 2025.
  • The last three reported values for EBIT Margin were 26.15% (Q3 2025), 1287.87% (Q2 2025), and 788.76% (Q1 2025) per Business Quant data.